AgomAb Therapeutics NV (AGMB) vs BlossomHill Therapeutics (BLSM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
BlossomHill Therapeutics is the larger company by market cap ($555.6 million vs $447.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | BLSM |
|---|---|---|
| Share price | $9.08 | $17.48 |
| Market cap | $447.17M | $555.60M |
| 1-day change | -1.52% | +3.55% |
| EPS (TTM) | $-2.08 | $-4.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.82 | $27.99 |
| 52-week low | $7.97 | $15.25 |
| Distance from 52-week high | -49.05% | -37.55% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +314.87% | +102.52% |
| Average volume | 140.06K | 258.35K |
| Shares outstanding | 49.25M | 31.78M |
| Employees | 62 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AgomAb Therapeutics NV
AGMB stock →AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees
About BlossomHill Therapeutics
BLSM stock →BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
AGMB vs BLSM FAQ
Which is bigger, AgomAb Therapeutics NV or BlossomHill Therapeutics?
BlossomHill Therapeutics (BLSM) is larger, with a market capitalization of $555.60M compared with $447.17M for AgomAb Therapeutics NV (AGMB).
Are AgomAb Therapeutics NV and BlossomHill Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for AgomAb Therapeutics NV and Biotechnology: Pharmaceutical Preparations for BlossomHill Therapeutics.